Abstract
No public abstract is available from the verified source records.
Kaori Sumi, Teruaki Masuda, Sae Mochizuki, Hidekazu Kondo, Naohiko Takahashi, Noriyuki Kimura
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Idiopathic inflammatory myopathies
10.1038/s41572-021-00321-x · 2021
Idiopathic inflammatory myopathies
10.1016/j.ncl.2014.04.007 · 2014
Cardiac involvement and anti-striational antibodies in immune-mediated necrotizing myopathy
10.1016/j.jns.2025.123414 · 2025
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily
10.1073/pnas.94.21.11514 · 1997
Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint
10.3389/fimmu.2020.00951 · 2020
Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: potential role in cardiovascular diseases
2021
Growth and differentiation factor 15 is secreted by skeletal muscle during exercise and promotes lipolysis in humans
10.1172/jci.insight.131870 · 2020
The cytokine growth differentiation factor-15 and skeletal muscle health: portrait of an emerging widely applicable disease biomarker
10.3390/ijms232113180 · 2022
The myokine GDF-15 is a potential biomarker for myositis and associates with the protein aggregates of sporadic inclusion body myositis
datacite
Confidence 0%
10.1016/j.cyto.2019.154966 · 2020
The emerging role of Growth Differentiation Factor 15 as a potential disease biomarker in juvenile dermatomyositis
10.1093/rheumatology/kead654 · 2025
The diagnostic value of GDF-15 for myocardial involvement in idiopathic inflammatory myopathy
10.1093/rheumatology/keaa721 · 2021
Activity prediction modeling based on a combination of growth differentiation factor 15 and serum biomarker levels in dermatomyositis and polymyositis
10.1016/j.arcmed.2024.103058 · 2024
119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, the Netherlands
10.1016/j.nmd.2004.02.006 · 2004
188th ENMC international workshop: inclusion body myositis, 2–4 December 2011, Naarden, the Netherlands
10.1016/j.nmd.2013.08.007 · 2013
224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies. Zandvoort, the Netherlands, 14–16 October 2016
10.1016/j.nmd.2017.09.016 · 2018
Revised equations for estimated GFR from serum creatinine in Japan
10.1053/j.ajkd.2008.12.034 · 2009
GDF-15 is associated with sarcopenia and frailty in acutely admitted older medical patients
10.1002/jcsm.13513 · 2024
Growth differentiation factor 15 as a useful biomarker for mitochondrial disorders
10.1002/ana.24506 · 2015
Growth and differentiation factor 15 as a biomarker for mitochondrial myopathy
10.1016/j.mito.2019.10.005 · 2020
Retrospective study shows that serum levels of chemokine CXCL10 and cytokine GDF15 support a diagnosis of sporadic inclusion body myositis and immune-mediated necrotizing myopathy
10.3390/brainsci13101369 · 2023
Growth differentiation factor-15 as an emerging biomarker for identifying myositis
10.1080/1744666x.2022.2021879 · 2022
Growth differentiation factor-15 and risk of CKD progression
10.1681/asn.2016080919 · 2017
Growth differentiation factor-15 and incident chronic kidney disease: a population-based cohort study
10.1186/s12882-021-02558-w · 2021
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure
10.1016/j.jacc.2007.04.091 · 2007
Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure trial
10.1161/circulationaha.109.928846 · 2010
No additional external references are available.